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Intrinsic antiviral host factors confer cellular defense by limiting virus replication and 30	
are often counteracted by viral countermeasures.  We reasoned that host factors that 31	
inhibit viral gene expression could be identified by determining proteins bound to viral 32	
DNA (vDNA) in the absence of key viral antagonists.  Herpes simplex virus 1 (HSV-1) 33	
expresses ICP0, which functions as an E3 ubiquitin ligase required to promote infection.  34	
Cellular substrates of ICP0 have been discovered as host barriers to infection, but 35	
mechanisms for inhibition of viral gene expression are not fully understood.  To identify 36	
restriction factors antagonized by ICP0, we compared proteomes associated with vDNA 37	
during HSV-1 infection with wild-type (WT) virus and mutant lacking functional ICP0 38	
(ΔICP0).  We identified the cellular protein Schlafen 5 (SLFN5) as an ICP0 target that 39	
binds vDNA during HSV-1 ΔICP0 infection.  We demonstrated that ICP0 mediates 40	
ubiquitination of SLFN5 which leads to its proteasomal degradation.  In the absence of 41	
ICP0, SLFN5 binds vDNA to repress HSV-1 transcription by limiting accessibility of RNA 42	
polymerase II to viral promoters.  These results highlight how comparative proteomics 43	
of proteins associated with viral genomes can identify host restriction factors, and 44	
reveal that viral countermeasure can overcome SLFN antiviral activity.  45	
 46	
Intrinsic host defenses function cooperatively to limit replication and spread of viral pathogens 47	
from the outset of nuclear infection1–4.  Conversely, evolution provides viruses with elegant 48	
strategies to subvert these host defenses, often through binding and inducing degradation of 49	
the cellular restriction factors1,5–12.  Although there is rapidly expanding knowledge of 50	
restriction factors for RNA viruses, there is a critical need to identify and better understand 51	
intrinsic cellular defenses against viruses with DNA genomes.  Since viruses hijack the cellular 52	
ubiquitin machinery to modify the host cell proteome and subvert these inhibitory defenses, 53	
identifying substrates for viral-induced ubiquitination can reveal cellular restriction factors5–7.  54	
The immediate early ICP0 viral protein of herpes simplex virus type 1 (HSV-1) promotes 55	
transactivation of viral genes and regulates reactivation from latency13–15.  ICP0 contains an E3 56	
ubiquitin ligase domain that antagonizes host defenses through proteasomal degradation of 57	
intrinsic antiviral factors in infected cells13,16-36.  Cellular substrates of ICP0 have been discovered 58	
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as host barriers to infection, but their mechanisms for inhibition of viral gene expression are not fully 59	
understood33–36.  We sought to discover antiviral host factors that limit HSV-1 infection by 60	
identifying proteins bound to viral DNA genomes (vDNA) in the absence of ICP0.  The Isolation 61	
of Proteins On Nascent DNA (iPOND) technique was developed as a way of identifying 62	
proteins associated with newly-synthesized DNA during replication37.  This approach involves 63	
metabolic incorporation of 5-ethynyl-2´-deoxyuridine (EdU) into newly-synthesized DNA, which 64	
can be biotinylated by click chemistry to allow affinity purification and determination of proteins 65	
bound to DNA by mass spectrometry-based proteomics.  It has recently been adapted to 66	
isolate and define proteins accumulated on nuclear-replicating vDNA genomes38–40.  We 67	
reasoned that antiviral factors that are targeted by ICP0 to overcome inhibition of viral 68	
transcription and replication would be associated with the viral genome in its absence and 69	
could be identified by iPOND and mass spectrometry.  By comparing vDNA-associated 70	
proteomes for wild-type HSV-1 and a ΔICP0 mutant, we identified the cellular SLFN5 protein 71	
as a target for ICP0-mediated degradation.  SLFN5 is a nuclear member of the Schlafen family 72	
of proteins that have been implicated in immune cell proliferation, differentiation and antiviral 73	
retsriction41–50.  Employing iPOND in a comparative proteomics approach presents an 74	
approach to identify substrates of viral antagonists and reveal host factors that act on viral 75	
DNA genomes to restrict infection.   76	
 77	
Results 78	
Comparative proteomics identifies SLFN5 on vDNA in the absence of ICP0.  Here we 79	
employed iPOND to identify proteins differentially associated with vDNA during WT or ΔICP0 80	
HSV-1 infection of human foreskin fibroblasts (HFFs) at 8 hours post-infection (hpi) (Fig. 1a).  81	
Host factors known to be substrates of ICP0-mediated degradation were isolated from viral 82	
genomes during ΔICP0, but not WT, HSV-1 infection (Fig. 1b).  We performed three-83	
dimensional principal component analysis (PCA) clustering to identify cellular factors that 84	
showed binding profiles similar to known ICP0 substrates DNA-PKcs, IFI16, and PML (Fig. 1c; 85	
Extended Data Fig. 1a).  Clustered proteins enriched on ΔICP0 relative to WT HSV-1 86	
genomes were considered putative ICP0 substrates that are targeted for degradation to 87	
overcome cellular antiviral restriction (Extended Data Fig. 1b,c).  Among these putative 88	
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substrates, we identified the SLFN5 protein (Fig. 1c).  Identification of SLFN5 in iPOND-MS 89	
from uninfected cells may reflect functions on cellular DNA41–45.  Although the cytoplasmic 90	
SLFN11 protein has been reported to inhibit virus infection by controlling protein synthesis46, 91	
no antiviral function has been ascribed to nuclear SLFN proteins, and no viral 92	
countermeasures to SLFN proteins have been identified.   93	
ICP0 targets SLFN5 for ubiquitination and poteasomal degradation.  To explore SLFN5 94	
during HSV-1 infection, we first confirmed by immunoblotting that SLFN5 was differentially 95	
bound to ΔICP0 EdU-labelled vDNA during HSV-1 infection (Fig. 1d).  The absence of SLFN5 96	
in the proteome isolated on vDNA by iPOND-MS from WT HSV-1 infections suggests that it is 97	
depleted by ICP0.  Proteins isolated by iPOND were therefore also examined in whole cell 98	
proteome abundance data generated over a time-course of HSV-1 infection51.  SLFN5 99	
decreased in protein abundance in a similar fashion to known ICP0 substrates DNA-PKcs, 100	
PML, IFI16, USP7, and ATRX (Fig. 1e; Extended Data Fig. 1d).  These SLFN5 proteomics 101	
results were further validated by immunoblot analysis over a time-course of infection, where 102	
SLFN5 levels decreased similarly to other known substrates of ICP0 during WT HSV-1 103	
infection (Fig. 1f).  The decrease in SLFN5 expression was specific, since the levels of other 104	
family members were not decreased, including SLFN11 (Fig. 1f) which has been assigned 105	
antiviral functions46.  Expression of a functionally inactive ICP0 RING domain (ΔRING) did not 106	
decrease SLFN5 protein levels during HSV-1 infection (Fig. 1f).  Furthermore, the reduction in 107	
SLFN5 in HSV-infected cells was abolished by treatment with the proteasome inhibitor MG132 108	
(Fig. 1g).  When protein synthesis was inhibited by cycloheximide, SLFN5 protein was rapidly 109	
turned over during WT, but not ΔRING, HSV-1 infection (Fig. 1h).  Together, these data 110	
identify SLFN5 as a target of ICP0-mediated proteasomal degradation.  Furthermore, the 111	
observation that SLFN5 accumulates on viral genomes in the absence of ICP0, similar to other 112	
antiviral substrates of ICP0, suggests that SLFN5 is a putative host restriction factor.   113	
We next investigated the requirement for SLFN5 reduction during HSV-1 infection.  To confirm 114	
that ICP0 is sufficient to induce SFLN5 degradation independently of other viral factors, we 115	
employed an adenovirus transduction vector with doxycycline-inducible expression of ICP0 116	
(Fig. 2a).  Expression of ICP0 reduced SLFN5 protein abundance, with detectable levels of 117	
SLFN5 polyubiquitination following immunoprecipitation.  This was further supported by co-118	
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transfection of tagged-SLFN5 with ICP0 in HEK293T cells, which lack endogenous SLFN546 119	
(Extended Data Fig. 2a,b), confirming ICP0 RING-dependent degradation of SLFN5.  We 120	
next examined whether targeting of SLFN5 is due to direct interaction with ICP0 or is mediated 121	
indirectly through the degradation of PML nuclear bodies (NBs)52–55.  In PML depleted cells, 122	
SLFN5 was degraded by ICP0, suggesting PML-independent direct targeting (Fig. 2b).  The 123	
RING-dependent degradation of endogenous SLFN5 was also consistently observed in other 124	
cell lines (Extended Data Fig. 2c,g).  Since ICP0 has SUMO-targeting properties56,57 and 125	
SLFN5 has been predicted as a SUMO-dependent substrate for ubiquitination58, we examined 126	
SLFN5 degradation in cells depleted for the SUMO-conjugating enzyme UBC9 (Extended 127	
Data Fig. 2h).  SLFN5 degradation was unaffected by UBC9 depletion, suggesting a SUMO-128	
independent mechanism of ICP0 degradation.  We therefore examined whether ICP0 interacts 129	
directly with SLFN5.  While some human and mouse SLFN proteins have been detected in the 130	
cytoplasm, human SLFN5 is predominantly nuclear.  Immunofluorescence demonstrated 131	
SLFN5 to be diffusely nuclear in uninfected cells but to colocalize in nuclear puncta with WT 132	
and ΔRING mutant ICP0 at 2 hpi (Fig. 2c,d).  SLFN5 signal decreased by 4 hpi in WT HSV-133	
infected cells due to ICP0-mediated degradation, and relocalized with ΔRING into larger 134	
structures that are presumably sites of vDNA accumulation (Fig. 2d).  Endogenous SLFN5 co-135	
immunoprecipitated with ICP0 from WT HSV-1 infected cells at 2 hpi (Fig. 2e) but not at 4 hpi, 136	
a time point at which SLFN5 levels were significantly diminished.  To identify the domain of 137	
SLFN5 that interacts with ICP0 we constructed a series of GFP-tagged SLFN5 deletion 138	
mutants (Fig. 2f,g).  Full-length SLFN5 and truncation mutants mainly localized to the nucleus 139	
(Extended Data Fig. 3a), except for the Δ730-891 and Δ540-891 mutants which lack a 140	
predicted nuclear localization sequence (NLS) in the carboxyl (C)-terminal region (aa812-815, 141	
RKRK)59.  We mapped the ICP0-binding region of SLFN5 by co-immunoprecipitation from co-142	
transfected HEK293T cells.  ICP0 interacted with full-length SLFN5 and mutants that retain 143	
residues 730-891, but their interaction was diminished in the absence of the C-terminal region 144	
(Fig. 2f,g).  Since C-terminal mutants lack the SLFN5 NLS, we also tested interaction with a 145	
cytoplasmic ICP0 mutant (cICP0)60, but no interaction was detected (Extended Data Fig. 3b).  146	
These data suggest ICP0 binds the C-terminal region of nuclear SLFN5.  To verify the 147	
specificity of the ICP0-SLFN5 interaction among other SLFN proteins, we assessed ICP0 148	
interaction with SLFN11 via co-immunoprecipitation.  Under conditions where ICP0 interacted 149	
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with SLFN5, we did not detect an interaction with SLFN11 (Fig. 2h).  Proteins that interact with 150	
viral factors such as ICP0 often contain intrinsically disordered regions61 which we observed in 151	
the C-terminal region of SLFN5 but not SLFN11 (Extended Data Fig. 3c) and may facilitate 152	
association with ICP0.  As final evidence of targeted ubiquitination, we performed in vitro 153	
ubiquitination assays using recombinant proteins.  These assays showed that full-length 154	
SLFN5 produced by bacteria or in vitro translation could be ubiquitinated by recombinant ICP0 155	
(Fig. 2i; Extended Data Fig. 2i).  In contrast, ICP0 did not ubiquitinate either SLFN11 or the 156	
SLFN5 Δ730-891 truncation that lacks ICP0 binding.  Together, these data demonstrate that 157	
ICP0 binds SLFN5 and is sufficient for ubiquitination and proteasomal degradation 158	
independently of other viral cofactors.   159	
SLFN5 associates with vDNA in the absence of ICP0.  We used immunofluorescence and 160	
confocal microscopy to localize SLFN5 during HSV-1 infection (Fig. 3).  HFF cells were 161	
infected with HSV-1 grown in the presence of ethynyl-tagged deoxycytidine (EdC) to label 162	
vDNA that can be detected by click chemistry62.  SLFN5 co-localized with input HSV-1 163	
genomes in puncta during early times of infection, including prematurely uncoated cytosolic 164	
genomes and incoming genomes in the nucleus (Fig. 3a-c).  As previously reported62, at early 165	
times input vDNA in the nucleus colocalizes with PML nuclear bodies (NBs) before PML is 166	
degraded by ICP0 (Fig. 3a-c).  Some PML NBs also colocalize with SLFN5 foci at sites of 167	
input vDNA (Fig. 3b).  By 4 hpi the PML has been decreased via ICP0 degradation but 168	
remaining SLFN5 colocalized with vDNA as pre-replication foci are formed.  At early times of 169	
infection, the viral transcriptional activator ICP4 marks site of gene expression from incoming 170	
viral genomes (Extended Data Fig. 4a).  SLFN5 partially localized with these virus-induced 171	
structures, further supporting association with incoming vDNA genomes.  We then examined 172	
SLFN5 localization at later times when vDNA synthesis had been initiated at viral replication 173	
compartments (VRCs).  We labeled sites of vDNA synthesis by EdC incorporation and 174	
detection via click chemistry (Fig. 3d).  To allow comparison between WT and ΔICP0 mutant 175	
HSV-1 infection, we added acycloguanosine (ACG) to limit VRC expansion.  During WT HSV-1 176	
infection, the staining for SLFN5 decreased and did not colocalize with vDNA (Fig. 3d,e) or 177	
with VRCs located by staining for the DNA binding protein ICP8 (Extended Data Fig. 4b).  In 178	
contrast, SLFN5 colocalized with vDNA and VRCs during infection with ΔICP0 mutant HSV-1 179	
(Fig. 3d; Extended Data Fig. 4b).  Quantification showed a high colocalization coefficient for 180	
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vDNA and SLFN5 in cells infected with HSV-1 ΔICP0 (Fig. 3e), with high-resolution Z-series 181	
imaging suggesting vDNA to be entrapped by a shell of SLFN5 in the nucleus (Fig. 3f).  These 182	
observations are similar to patterns detected for the antiviral protein PML (Extended Data Fig. 183	
4b), which was previously reported to entrap nuclear HSV-1 DNA62.  Together with the iPOND 184	
data, these results support the conclusion that SLFN5 binds vDNA in the absence of ICP0.  185	
ICP0 counteracts SLFN5-mediated inhibition of HSV-1 infection.  To assess the functional 186	
relevance of SLFN5 degradation, we used a lentiviral vector to generate cells expressing 187	
shRNAs to SLFN5 (Extended Data Fig. 5a).  We compared vDNA replication in the presence 188	
and absence of SLFN5 during WT and ΔRING HSV-1 infection (Fig. 4a, Extended Data Fig. 189	
5b).  Accumulation of vDNA for WT HSV-1 was moderately increased in the absence of 190	
SLFN5 (~2-fold).  However, vDNA abundance of ΔRING HSV-1 was significantly increased 191	
(>10-fold) in SLFN5-depleted cells relative to infected control cells (Fig. 4a).  Consistent with 192	
increased vDNA replication, SLFN5 depletion resulted in a 3- and 13-fold increase in progeny 193	
production of ΔRING virus at 24 and 48 hpi, respectively (Fig. 4b).  SLFN5 depletion also 194	
increased accumulation of viral proteins for ΔRING virus, with the most pronounced effect at 195	
lower virus MOIs (Extended Data Fig. 5c).  Since SLFN5 has been implicated in control of cell 196	
growth43 and morphology44, we examined the effect of SLFN5 on cell proliferation.  We did not 197	
observe any change in morphology and growth rate when SLFN5 was depleted in HeLa cells 198	
(Extended Data Fig. 5d-f), suggesting a direct antiviral effect on HSV-1 replication rather than 199	
an indirect effect on cell growth.  We confirmed that the effects of SLFN5 depletion on HSV-1 200	
replication were achieved when both siRNA-mediated knockdown and single guide RNA-201	
mediated CRISPR/Cas9 knockout (KO) were employed (Fig. 4c; Extended Data Fig. 5g).  To 202	
complement the knockdown approach, we also examined whether ectopic SLFN5 over-203	
expression impacted HSV-1 replication.  We examined vDNA replication in SLFN5 KO HeLa 204	
cells which had been transduced with lentiviral vector to express HA-tagged SLFN5 under a 205	
tetracycline-inducible promoter.  While vDNA levels of WT virus were not significantly altered, 206	
levels of vDNA during ΔRING infection were significantly decreased in the presence of SLFN5 207	
when compared to empty vector control cells (Fig. 4d).  The impact of SLFN5 depletion and 208	
reconstitution on ΔRING virus supports our conclusion that SLFN5 restricts HSV-1 infection 209	
and this restriction is alleviated by ICP0 during WT HSV-1 infection.  One possible way that 210	
SLFN5 could affect viral replication is via the putative helicase activity63.  To determine 211	
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whether the Walker A helicase motif of SLFN5 affects HSV-1 replication, SLFN5 KO cells were 212	
transduced with adenoviral vectors expressing WT or Walker A mutant (K584A) SLFN5.  213	
Expression of both WT and mutant SLFN5 reduced HSV-1 protein expression and progeny 214	
production compared to the control, demonstrating helicase-independent antiviral activity (Fig. 215	
4e,f).  We also tested the impact of SLFN5 overexpression on HSV-1 replication for full-length 216	
SLFN5 compared to the Δ730-891 truncation that lacks the ICP0 binding domain (Extended 217	
Data Fig. 6a).  When SLFN5 proteins were induced in cells that were then infected with HSV-1,  218	
only full-length SLFN5 was able to inhibit ΔRING HSV-1 replication (Extended Data Fig. 6b,c).  219	
We further addressed the specificity of the inhibitory effect of SLFN5 by analyzing additional 220	
SLFN family proteins and other viruses.  It has been reported that cytoplasmic SLFN11 inhibits 221	
protein synthesis during HIV infection46.  Depletion of SLFN11 using siRNA did not affect HSV-222	
1 protein expression or vDNA replication (Fig. 4g,h).  We found that HSV-2 was also able to 223	
decrease SLFN5 levels (Extended Data Fig. 7a) and showed increased viral protein 224	
expression when SFLN5 was depleted (Extended Data Fig. 8b).  In contrast, other DNA 225	
viruses (HCMV or Ad5) neither degraded SLFN5 (Extended Data Fig. 7b,c) nor were 226	
restricted by SLFN5 (Extended Data Fig. 8b,c).  These results suggest virus specificity in 227	
SLFN family-mediated antiviral restriction. 228	
SLFN5 suppresses HSV-1 gene transcription by limiting RNA polymerase accessibility.  229	
We next explored whether SLFN5 impacts HSV-1 gene transcription.  We analyzed 230	
accumulation of viral gene transcripts in the presence of viral DNA polymerase inhibitor 231	
phosphonoacetic acid (PAA) in either control or SLFN5 knockdown cells.  Viral replication was 232	
completely blocked by PAA (Fig. 5a), enabling transcript levels to be measured from incoming 233	
vDNA.  Viral transcription was enhanced for the immediate-early gene ICP27 and early gene 234	
TK in SLFN5-depleted cells compared to controls (Fig. 5a).  The increase in gene expression 235	
was further supported by concomitant increases in early viral protein levels during infection in 236	
the presence of PAA (Fig. 5b).  Late protein production is dependent on vDNA replication, and 237	
therefore proteins such as VP21 were not detected.  Since RNA levels are determined by the 238	
balance between synthesis and decay, we analyzed de novo transcription and mRNA stability 239	
by 4sU metabolic pulse labelling (Fig. 5c and 5d).  In SLFN5 knockdown cells, both total 240	
mRNA and nascent mRNA for viral genes were increased by 3-fold (Fig. 5c).  We calculated 241	
similar RNA decay rates for both ICP27 and TK transcripts when compared to SLFN5 242	
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knockdown cells (Fig. 5d).  These results indicate that SLFN5 inhibits viral gene transcription 243	
but does not impact mRNA stability.   244	
To assess whether SLFN5 effects were specific to HSV-1, we examined infection with the 245	
HCMV.  SLFN5 depletion enabled increased viral protein expression of viral proteins such as 246	
IE1/IE2 and UL44 within the first 24 hours of infection but was decreased at later times 247	
(Extended Data Fig. 8b).  We saw similar effects when examining mRNA levels for 248	
immediate-early and late viral transcripts (Extended Data Fig. 9a,b).  HCMV replication yield 249	
was also not significantly changed in SLFN5-deleted HFF cells (Extended Data Fig. 9c).  One 250	
difference between HSV-1 and HCMV is the time course of infection, with HSV-1 replication 251	
being much quicker than HCMV.  Since SLFN5 has been shown to regulate STAT1-mediated 252	
gene transcription and interferon-stimulated genes (ISG) expression, depletion of SLFN5 may 253	
generate higher levels of ISG signaling that results in lower levels of HCMV replication.  We 254	
observed that SLFN5 knockdown led to higher levels of ISG15 expression, and this was further 255	
increased during HCMV infection (Extended Data Fig. 8b,d).  Therefore, we propose that 256	
SLFN5 has a direct role in the cellular restriction of HSV-1 infection prior to the induction of 257	
innate immune defences and ISG expression. 258	
Finally, we employed chromatin immunoprecipitation (ChIP) assays to detect association of 259	
cellular proteins with the HSV-1 genome.  When we used an antibody to HA-tagged SLFN5, 260	
ChIP pulldown from ΔRING virus infection recovered increasing yields of vDNA over time 261	
(Extended Data Fig. 10a).  Although WT HSV-1 replicates to a higher level than the ΔRING 262	
mutant, we observed less vDNA isolated by HA ChIP during WT HSV-1 infection, consistent 263	
with SLFN5 degradation by ICP0.  We found that SLFN5 bound indiscriminately along the 264	
length of the HSV-1 genome, suggesting that it does not recognize a specific DNA sequence 265	
(Extended Data Fig. 10b).  Since SLFN5 inhibits viral gene expression (Fig. 5a,c), we 266	
examined whether it impacts RNA polymerase II (RNAP II) binding to transcription start sites 267	
(TSS) on viral promoters.  ChIP assays showed that RNAP II binding at viral promoters was 268	
significantly higher in SLFN5 knockdown cells than in controls (Fig. 5e).  Since the defects of 269	
an ICP0 mutant can be overcome at high MOIs, we also examined RNAP II ChIP with 270	
increasing MOI of HSV-1 (Fig. 5f).  As expected, the effect of SLFN5 loss on the degree of 271	
RNAP II binding to the viral genome decreased as the MOI of ΔRING virus increased from MOI 272	
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1 to 10.  In addition, this point was further strengthened by examining the effect of SLFN5 273	
depletion on virus yield as ΔRING virus MOI increases (Fig. 5g).  The difference in virus 274	
particles produced in the absence of SLFN5 decreased as MOI increased from 1 to 10.  275	
Together these data demonstrate MOI-dependent restriction of ICP0 mutant virus replication 276	
by SLFN5.  These results suggest that SLFN5 restricts HSV-1 infection by binding vDNA to 277	
prevent access to RNAP II, and thus inhibiting transcription of viral promoters. 278	
 279	
Discussion 280	
Our study presents an innovative approach to identify host restriction factors by defining 281	
proteins associated with virus genomes in the absence of a key viral immune antagonist.  We 282	
found the human SLFN5 protein associates with HSV-1 genomes in the absence of the viral 283	
ICP0 protein, a critical regulator of host intrinsic immune defenses to HSV-1 infection.  The 284	
SLFN proteins have been implicated in multiple functions41,42, which include suppression of 285	
retrovirus replication via inhibition of protein synthesis by SLFN1146,64 and inhibition of 286	
influenza virus by SLFN1447.  The SLFN proteins have also been indirectly linked to virus 287	
infection via interferon signaling45,47.  Our results present the first example of direct inhibition of 288	
virus gene expression through SLFN5 binding to vDNA in the nucleus.  Our model for antiviral 289	
activity proposes that SLFN5 binding to vDNA inhibits transcription from viral genomes by 290	
limiting accessibility to RNAP II (Fig. 5h).  We demonstrate that the E3 ubiquitin ligase activity 291	
of ICP0 marks SLFN5 for proteasome-mediated degradation during WT HSV-1 replication to 292	
promote the efficient initiation of viral transcription.  This represents the first report of a viral 293	
countermeasure targeting a member of the SLFN family, highlighting the importance of 294	
intrinsically expressed host factors in the inhibition of vDNA pathogens.  Our comparative 295	
proteomics approach demonstrates how antiviral host restriction factors can be revealed by 296	
identifying proteomes associated with vDNA genomes in the absence of viral anatagonists.  297	
This approach could be extended to other DNA viruses where targets of viral proteins that 298	
promote infection are unknown.       299	
 300	




Cell culture.  All cells were obtained from the American Type Culture Collection (ATCC) 302	
without independent authentication and grown in a 5% CO2 humidified incubator at 37°C.  303	
Primary human foreskin fibroblasts (HFFs; ATCC SCRC-1041), HEK293 (ATCC CRL-1573), 304	
HEK293T (ATCC CRL-3216), HeLa (ATCC CCL-2), U2OS (ATCC HTB-96), Vero (ATCC CCL-305	
81), and retinal pigmented epithelial (RPE-1; ATCC, CRL-4000) cells were grown in DMEM 306	
(Gibco) supplemented with 10% fetal bovine serum (FBS) (VWR) and penicillin (100 307	
U/ml)/streptomycin (100 µg/ml) (Invitrogen).  Cells were transfected using Lipofectamine 2000 308	
or RNAiMAX (Invitrogen) following the manufacturer’s instructions.  309	
 310	
Plasmids.  The pcDNA6.2 plasmids expressing C-terminal V5-tagged SLFN5 and SLFN11 311	
were kindly provided by Sara L. Sawyer (University of Colorado Boulder).  Plasmids 312	
expressing GFP-SLFN5 (pcDNA6.2-/N-EmGFP-DEST), His-SLFN5 (pDEST17), Adenoviral 313	
SLFN5-V5 (pAd/CMV/V5-DEST), and SLFN5-HA under a tetracycline-inducible promoter 314	
(pLIX_402, gifted from David Root, Addgene plasmid # 41394) were created using Gateway 315	
recombination technology (Invitrogen).  Point and deletion mutants of SLFN5 were generated 316	
using the Stratagene QuickChange Site-Directed Mutagenesis protocol.  pLKO.1-shSLFN5 317	
plasmids (RHS4533-EG162394) were purchased from Dharmacon.  pX330-GFP-Cas9 plasmid 318	
for human SLFN5 knockout was constructed with single guide RNA (5’-319	
GATGCAGGAAAAGTCACCCT-3’).   320	
 321	
Viruses and Titration.  Parental virus HSV-1 strain was 17syn+ and the matched ICP0 322	
deletion mutant ΔICP0 was dl140365.  The ICP0 ΔRING domain deletion mutant was FXE66.  323	
Viruses were kindly provided by Roger Everett (Glasgow, Scotland) propagated in Vero cells 324	
and titrated in U2OS cells.  For 5-ethynyl-2'-deoxycytidine (EdC) labelling of HSV-1 genomes, 325	
RPE cells were infected with HSV-1 (MOI 0.001) or ΔICP0 (MOI 0.5).  At 24 hpi, EdC was 326	
added at a final concentration of 0.5 µM.  Fresh EdC was pulsed into infected cultures at 24 h 327	
intervals until extensive cytopathic effect was observed.  Supernatants containing labelled 328	
viruses were clarified by centrifugation (423 xg for 10 min) and filtered through a 0.45 µm 329	
sterile filter and pelleted using a Beckman TLA100 Ultracentrifuge (33,800 xg for 3h at 4°C).  330	
Virion pellets were resuspended and pooled in 500 µl complete DMEM medium.  For HSV-1 331	
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plaque assays, U2OS cells in 12-well plates were infected with ten-fold serial dilutions of 332	
viruses.  After virus adsorption for 1h, the cells were overlaid with medium containing 0.5% 333	
carboxylmethylcellulose.  Plaques were stained with crystal violet at 3 days post infection. 334	
 335	
iPOND-MS.  We followed the iPOND protocol in virus infection previously described40,67. Per 336	
condition, eight 15 cm cell culture dishes containing HFF (1.0 x 107 cells) were mock-infected 337	
or infected with HSV-1 17syn+ or dl1403 at an MOI 3.  Cells were pulsed with 10 µM EdU 338	
(Invitrogen) for 15 min at 8 hpi.  Cells were fixed with 1% paraformaldehyde in PBS for 20 min 339	
at room temperature, crosslinking was quenched with 125 mM glycine and cells were scraped 340	
and harvested.  All conditions were performed in triplicate.  Samples were processed for 341	
iPOND as described previously40,67, with the following adaptations: after click chemistry 342	
reaction, cell pellets were resuspended in 0.5 ml of lysis buffer (20 mM HEPES pH 7.9, 400 343	
mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% Triton X-100) supplemented with 1 mM 344	
dithiothreitol (DTT) and cOmplete™ Protease Inhibitor Cocktail (Roche) and 1 mM PMSF and 345	
sonicated with a Bioruptor (Diagenode) for 20 min in 30 sec on/off cycles at a high intensity.  346	
Capture of DNA-protein complexes was carried out by incubating lysates with 120 µl 347	
streptavidin Dynabeads M-280 (Invitrogen) for 16 h at 4 °C in the dark. Beads were washed 348	
once in lysis buffer, once in 1 M NaCl, four times in wash buffer (20 mM HEPES pH 7.4, 110 349	
mM KOAc, 2 mM MgCl2, 0.1% Tween 20, 0.1% Triton X-100, 150 mM NaCl) and once in PBS.  350	
Then, 60 µl of 1X LDS sample buffer (Invitrogen) containing 10% DTT was used to elute 351	
proteins from the beads. Eluted proteins were boiled at 95 °C for 45 min to reverse crosslinks.  352	
iPOND isolates were separated on ~0.8 cm on a 10% Bis-Tris Novex mini-gel (Invitrogen) 353	
using the MOPS buffer electrophoresis system.  The gel was stained with Coomassie Brilliant 354	
Blue and the band excised.  Gel segments were destained with 50% methanol/1.25% acetic 355	
acid, reduced with 5 mM DTT, and alkylated with 40 mM iodoacetamide (Sigma).  Gel pieces 356	
were then washed with 20 mM ammonium bicarbonate (Sigma) and dehydrated with 357	
acetonitrile (Thermo Scientific).  Trypsin (Promega) (5 ng/µl in 20 mM ammonium bicarbonate) 358	
was added to the gel pieces and proteolysis was allowed to proceed overnight at 37 °C.  359	
Peptides were extracted with 0.3% trifluoroacetic acid (J.T.Baker), followed by 50% acetonitrile.  360	
Extracts were combined and the volume was reduced by vacuum centrifugation.  Tryptic 361	
digests were analyzed by LC-MS/MS on a hybrid LTQ Orbitrap Elite mass spectrometer 362	
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(Thermo) coupled with a nanoLC Ultra (Eksigent Technologies).  Peptides were separated by 363	
reverse phase (RP)-HPLC on a nanocapillary column, 75µm id x 15 cm Reprosil-pur 3µM, 120 364	
A (Dr. Maisch, HPLC GmbH) in a Nanoflex chip system (Eksigent). Mobile phase A consisted 365	
of 1% methanol (Fisher)/0.1% formic acid (Thermo Fisher Scientific) and mobile phase B of 1% 366	
methanol/0.1% formic acid/80% acetonitrile. Peptides were eluted into the mass spectrometer 367	
at 300 nl/min with each RP-LC run comprising a 120-min gradient from 5 to 35% B. The mass 368	
spectrometer was set to repetitively scan m/z from 300 to 1800 (r = 240,000 for LTQ-Orbitrap 369	
Elite) followed by data-dependent MS/MS scans on the twenty most abundant ions, with a 370	
minimum signal of 1500, dynamic exclusion with a repeat count of 1, repeat duration of 30 s, 371	
exclusion size of 500 and duration of 60 s, isolation width of 2.0, normalized collision energy of 372	
35, and waveform injection and dynamic exclusion enabled.  FTMS full scan AGC target value 373	
was 1x106, whereas MSn AGC was 1x104, respectively.  FTMS full scan maximum fill time was 374	
500 ms, whereas ion trap MSn fill time was 50 ms; microscans were set at one. FT preview 375	
mode, charge state screening, and monoisotopic precursor selection were all enabled with 376	
rejection of unassigned and 1+ charge states. 377	
 378	
MS Data Processing and Database Searching.  MS raw files were analyzed by MaxQuant 379	
software version 1.5.2.8. MS/MS spectra were searched by the Andromeda search engine 380	
against the Human UniProt FASTA database (9606; 136,251 entries) (version July 2014).  The 381	
database included 247 common contaminants, discarded during data analysis.  The search 382	
included variable modifications of methionine oxidation and amino-terminal acetylation, and 383	
fixed modification of carbamidomethyl cysteine. Trypsin was specified as the digestive enzyme.  384	
Minimal peptide length was set to six amino acids and a maximum of two missed cleavages 385	
was allowed.  The false discovery rate (FDR) was set to 0.01 for peptide-spectrum matches 386	
(PSMs) and protein identifications. Protein grouping was enabled.  Peptide identification was 387	
performed with an allowed precursor mass deviation up to 4.5 ppm after time-dependent mass 388	
calibration and an allowed fragment mass deviation of 20 ppm.  Protein identification required 389	
at least one unique or razor peptide per protein group.  Label-free quantification in MaxQuant 390	
was performed using the intensity-based absolute quantification (iBAQ) algorithm.  The human 391	
proteome was searched using the match-between-runs functionality with the retention time 392	
alignment window set to 20 min and the match time window to 1 min.  Proteins were filtered to 393	
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eliminate the identifications from the reverse database, only identified by site and common 394	
contaminants.  Proteomics data are supplied in Supplementary Table 1. 395	
 396	
Data normalization and analysis.  MaxQuant output was filtered to remove identified 397	
common contaminants, proteins identified in the reverse protein database, and proteins that 398	
were quantified with 0 MS/MS counts.  Missing data were imputed using the BPCA method in 399	
the pcaMethods68 R package.  SLFN5 did not contain missing quantification data.  iBAQ 400	
intensities were transformed to log2 values, with unidentified values assigned as “NA”.  Data 401	
were normalized by subtracting the sample medians from log2 transformed iBAQ values within 402	
the respective samples.  The log2 fold changes of protein iBAQ quantification, used to 403	
compare protein abundance across samples, were calculated by comparing the averaged the 404	
log2 transformed and normalized iBAQ values for each replicate within the samples.  405	
Hypothesis testing was performed using unpaired, two-tailed student’s t-tests comparing the 406	
log2 transformed, normalized iBAQ values within the compared samples.  Multiple testing 407	
correction was not performed69.  Z-scores based on log2, normalized average iBAQ values 408	
were used to measure relative abundance of a protein within a sample. 409	
 410	
3D PCA Clustering Analysis.  PCA analysis was performed on the log2 transformed, 411	
normalized protein iBAQ data.  The protein abundance data from each replicate, within the 412	
mock, WT HSV and ΔICP0 HSV infections, were considered discretely within the PCA analysis 413	
(3 replicates x 3 samples = 9 total replicates).  PCA was performed using the “prcomp” function, 414	
within the R statistical software package.  Cluster grouping was evaluated by quantifying 415	
“loading” data distances with the first three dimensions of PCA space.  A specified protein was 416	
assigned as the cluster center and proteins within a sphere of 0.0125 units from the cluster 417	
center were clustered with the selected protein.  The sphere size was selected based on the 418	
range of the distribution of “loading” values for each of the first three PCA dimensions.  This 419	
approach does not assign proteins to unique clusters if a protein can be grouped with multiple 420	
distinct cluster centers.  Clusters for known ICP0 substrates (ATRX, IFI16, PML, and DNA-421	
PKcs) were generated and compared.  The intersection of the clusters contained the highest 422	
confidence predictions of ICP0 substrates within the iPOND dataset. 423	
 424	
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siRNA.  Gene knockdown experiments by siRNA were carried out using Lipofectamine 425	
RNAiMAX transfection reagent (Invitrogen).  siGENOME non-targeting control, SLFN5, and 426	
SLFN11 SMARTpool siRNAs were purchased from Dharmacon.  Cells in 12-well plates were 427	
transfected with 20 pmol/ml of siRNA and 2 µl of RNAiMAX.  428	
 429	
CRISPR/Cas9 KO.  For the HeLa SLFN5 KO generation, HeLa cells were transfected with 430	
pX330, which contains a GFP cassette and Cas9 nuclease, harboring sgSLFN5.  At 24h post 431	
transfection, GFP expressing cells were sorted by fluorescence-activated cell sorting (FACS) 432	
into 96-well plates for clonal expansion.  Immunoblot analysis of SLFN5 was used to validate 433	
the KO cell lines. 434	
 435	
Viral vector production.  Recombinant adenoviruses expressing ICP0 was obtained from P. 436	
Schaffer70.  Recombinant adenoviruses expressing SLFN5 and K584A mutant were produced 437	
using pAd/CMV/V5-DEST vector from Gateway technology (Invitrogen).  Then the plasmid was 438	
digested with PacI restriction enzyme and transfected into HEK293 cells and adenoviruses 439	
were collected at 7 days after transfection, according to the manufacturer’s protocol. 440	
 441	
Antibodies.  The following antibodies were used: anti-SLFN5 (Sigma-Aldrich; Cat.HPA017760; 442	
Lot.B96361), anti-SLFN11 (Novus Biologicals; Cat.NBP1-92368; Lot.H96783), anti-PML 443	
(Bethyl Laboratory; Cat.A301-167A, Santa Cruz; Cat.sc-966; Lot.H1413), anti-IFI16 (Santa 444	
Cruz; Cat.sc-8023; Lot.C1312), anti-ATRX (Santa Cruz; Cat.sc-15408), anti-DNA-PKcs (Santa 445	
Cruz; Cat.sc-5282; Lot.G280), anti-SUMO2+3 (Abcam; Cat.ab3742; Lot.GR8249-1), anti-446	
RNAP II (Santa Cruz; Cat.sc-56767), anti-GFP rabbit (Abcam; Cat.ab290; Lot.GR3251545-1), 447	
anti-GFP mouse (Millipore; Cat.MAB2510; Lot.2512480), anti-RAD50 (GeneTex; 448	
Cat.GTX70228; Lot.40186), anti-V5 (Santa Cruz; Cat.sc-271944; Lot.E2217), anti-HA (Abcam; 449	
Cat.ab9110; Lot.GR3217183-2), anti-GAPDH (GeneTex; Cat.GTX100118; Lot.42158), anti-α-450	
Tubulin (Santa Cruz; Cat.sc-69969; Lot.DO412), anti-β-Actin (Sigma-Aldrich; Cat.a5441; 451	
Lot.064M4789V), anti-KU70 (Abcam; Cat.ab83501; Lot.GR3176811-2), anti-Histone H3 452	
(Abcam; Cat.ab1791; Lot.GR3198176-1), anti-ICP0 (Santa Cruz; Cat.sc-53070; Lot. A0313), 453	
anti-ICP8 (gifted from David M. Knipe), anti-TK (Santa Cruz; Cat.sc-28037; Lot.K1813), anti-454	
VP21 and anti-gD (gifted from Gary H. Cohen), anti-IE1/IE2 (Virusys; Cat.P1215; 455	
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Lot.A1345070), anti-UL44 (Virusys; Cat.ca006-100; Lot.C1034151), adenovirus late protein 456	
antibody staining Hexon, Penton and Fiber (gift from James M. Wilson), and anti-DBP (gift 457	
from Arnold J. Levine). 458	
 459	
Immunoblot Analysis.  Cells were washed with PBS, and total cell extracts were prepared by 460	
boiling the cell pellets in NuPAGE 1X LDS Sample Buffer (Invitrogen).  Proteins were 461	
separated via SDS-PAGE and visualized using SuperSignal West Pico PLUS 462	
Chemiluminescent Substrate (Thermo Scientific) and G:Box imaging system (Syngene).  For 463	
SLFN5 half-life analysis in HSV-1 infection, HFF cells infected as indicated were incubated 464	
with 100 µg/ml of the protein synthesis inhibitor cycloheximide and collected at indicated time 465	
points.  Protein bands were quantified by densitometric analysis using ImageJ software. 466	
 467	
Immunofluorescence.  Cells on glass coverslips were infected with HSV-1 at an MOI 3.  Cells 468	
were grown on glass coverslips in 24-well plates and either mock infected or infected with the 469	
indicated virus.  Cells were washed in PBS, fixed in 4% paraformaldehyde for 10 min, 470	
permeabilized with 0.5% Triton X-100 in PBS for 10 min or pre-extracted to enhance 471	
immunofluorescence signal of DNA-protein complex with a buffer containing 20 mM HEPES 472	
pH7.9, 20 mM NaCl, 5 mM MgCl2, and 0.5 % NP40 for 1 min, and then fixed with 4% PFA prior 473	
to permeabilization with Triton-X100, and blocked with 3% bovine serum albumin for 1h.  Cells 474	
were incubated for 1h with primary antibodies followed by Alexa Fluor 488 anti-mouse or Alexa 475	
Fluor 647 anti-rabbit antibodies (Invitrogen) for 1h at room temperature.  Nuclei were 476	
visualized by staining with 4’,6-diamidino-2-phenylindol (DAPI).  Coverslips were mounted 477	
using ProLong Gold Antifade Reagent (Life Technologies) and immunofluorescence was 478	
visualized using a Zeiss LSM 710 Confocal microscope (Cell and Developmental Microscopy 479	
Core at UPenn) and ZEN 2011 software.  Images were processed using ImageJ.  For click 480	
chemistry imaging of HSV-1 DNA, cells were infected at an MOI of 3 with WT or ΔICP0 mutant 481	
HSV-1 prior to overlay with medium containing 0.5 µM EdC and 50 µM ACG on coverslips.  At 482	
6 hpi, cells were washed twice in CSK buffer (10 mM HEPES, 100 mM NaCl, 300 mM Sucrose, 483	
3 mM MgCl2, 5 mM EGTA), fixed in 1.8% formaldehyde, permeabilized with 0.5% Triton X-100 484	
in CSK buffer for 10 min, and blocked with 2% human serum (MP Biomedicals) in PBS for 30 485	
min.  EdC labelled vDNA was detected using Alexa Fluor 555 picolyl azide (C10638; Thermo 486	
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Fisher Scientific) as per manufacturer’s guidelines.  Zen black software (Zeiss) was used for 487	
image capture, generating cut mask channels, and calculating weighted colocalization 488	
coefficients.  High-resolution Z-series images were captured under LSM 880 Airy scan 489	
deconvolution settings using 1:1:1 capture conditions at 0.035 µm intervals.  Images were 490	
processed using Imaris (Bitplane) software to produce rendered 3D image reconstructions. 491	
 492	
Co-immunoprecipitation (Co-IP).  HEK293T cells (8 x 105 in 6-well plate) were transfected 493	
with the indicated plasmids using Lipofectamine 2000 (Invitrogen) according to the 494	
manufacturer’s protocol.  At 24 h post-transfection, cells were harvested in 500 µl of ice-cold 495	
co-IP buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Triton X-100, 50 mM NaF, 1mM 496	
Na3VO4) with protease inhibitors and sonicated with a Bioruptor for 5 min in 30 sec on/off 497	
cycles at a high intensity.  The lysates were cleared and incubated with 2 µg of anti-GFP 498	
antibody (Abcam) per sample for 4 h at 4°C with constant rotation.  The 20 µl of Dynabeads 499	
Protein G (Novex) were added to the samples and rotated at 4°C for 1 h.  The beads were 500	
washed four times with ice-cold co-IP buffer and resuspended in 1X LDS sample buffer.  For 501	
endogenous co-IPs, HFF cells (3 x 106 in 100-mm dish) were mock infected or infected with 502	
HSV-1 at an MOI of 3.  Cells were harvested at indicated time points and sonicated in 500 µl of 503	
co-IP buffer.  The clarified cell lysates were incubated with 2 µg of anti-ICP0 antibody (Santa 504	
Cruz) per sample for 4 h at 4°C.  The 20 µl of Dynabeads Protein G were incubated for 1 h.  505	
The beads were then washed with co-IP buffer and resuspended in 1X LSD sample buffer. 506	
 507	
Chromatin Immunoprecipitation (ChIP).  HeLa cells (8 x 106 per sample) were used for ChIP 508	
assays.  Cells were fixed with 1% formaldehyde for 15 min and then quenched with 125 mM 509	
glycine for 5 min at room temperature.  The cell pellet was washed with cold PBS, 510	
resuspended in 1 ml ChIP buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.5, 5 mM EDTA, 0.5% 511	
NP-40, 1% Triton X-100) supplemented with protease inhibitor and 1 mM PMSF.  The nuclei 512	
were collected by centrifugation at 2,000 xg for 5 min at 4°C and sonicated with a Bioruptor 513	
(Diagenode) for 10 min in 30 sec on/off cycles at a high intensity.  The cleared lysate was used 514	
for IP with anti-Histone H3 (Abcam; ab1791), anti-HA (Abcam; ab9110) antibodies, and the 515	
rabbit or mouse control IgG (Invitrogen; 31884; 31880).  Antibodies (5 µg) were incubated with 516	
the lysate for 4 h at 4°C with constant rotation.  Protein G Dynabeads (40 µl) were added to the 517	
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samples and rotated at 4°C for 1 h.  Each immune complex was washed five times in 1 ml of 518	
cold ChIP buffer, eluted by addition of 100 µl of Elution buffer (10 mM Tris-HCl pH 8.0, 5 mM 519	
EDTA, 1% SDS, 20 µg of RNase A) via boiling for 10 min at 95°C.  After elution of precipitated 520	
DNA, qPCRs were performed, the IgG background was subtracted, and the obtained data 521	
were normalized to input DNA and expressed as percent input. 522	
 523	
Reverse Transcription Polymerase Chain Reaction (RT-PCR) and Quantitative PCR 524	
(qPCR).  To measure mRNA levels, total RNA was isolated (RNeasy Mini Kit, Qiagen) and 525	
was reverse transcribed using the high-capacity RNA-to-cDNA Kit (Applied Biosystems).  The 526	
successful removal of DNA contamination was confirmed by amplifying the RNA in each 527	
sample without the reverse transcription reaction.  For DNA, total DNA was extracted using 528	
PureLink genomic DNA Mini Kit (Invitrogen).  Amplifying sequences were detected using 529	
Power SYBR green (Applied Biosystems) PCR reporter dye in a ViiA 7 real-time PCR system 530	
(Applied Biosystems).  Relative levels were normalized to RPLP0. 531	
 532	
Ubiquitination Assays.  To assess endogenous ubiquitination of SLFN5, cells were 533	
harvested in PBS containing 10 mM NEM and lysed in 1% SDS by boiling for 10 min.  The 534	
lysates were diluted to 0.1% SDS by adding TBST, and immunoprecipitated with anti-ubiquitin 535	
(P4D1, Santa Cruz) antibody, followed by immunoblotting.  For in vitro ubiquitination reactions, 536	
bacterially purified His-SLFN5 (500 ng) was incubated with 50 ng of UBE1 (UBPBio; B1100), 537	
250 ng of UBE2D1 (UBPBio; C1400), 5 µg of ubiquitin (UBPBio, E1100), and 2 mM ATP in the 538	
absence or presence of 100 ng of ICP0-His in 40 mM Tris-HCl pH 7.6, 50 mM NaCl, and 1 mM 539	
DTT at for 2 h at 4°C.  The reaction was stopped by boiling in LDS sample buffer and analyzed 540	
by immunoblotting using anti-SLFN5 antibody. 541	
 542	
RNA Transcription and Stability Profiling.  To assess relative RNA transcription rate and 543	
RNA half-life, cells were treated with 200 µM 4-thiouridine (4sU; Sigma T4509) for exactly 30 544	
min. Infection was stopped and RNA harvested using 1 ml TRIzol (Thermo Fisher Scientific), 545	
following manufacturer’s instructions.  A fraction of the total RNA was reserved as input, and 546	
the remaining 4sU-labeled nascent RNA was biotinylated using MTSEA-Biotin-XX (Biotium; 547	
90066) as previously described71,72.  Nascent RNA was separated from unlabeled RNA using 548	
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MyOne C1 Streptavidin Dynabeads (Thermo Fisher Scientific; 65-001), biotin was removed 549	
from nascent RNA using 100 mM dithiothreitol (DTT), and RNA was isopropanol precipitated.  550	
Total RNA (1 µg) and an equivalent volume of nascent RNA were converted to cDNA and 551	
qPCR was performed as described above.  Relative transcription rates were determined by the 552	
ΔΔCt method to compare nascent transcript levels between control and siRNA treated cells 553	
normalized to nascent GAPDH RNA.  RNA half-life was determined using the previously 554	
described formula t1/2 = -t × [ln(2)/DR] where t is the 4sU labeling time (0.5 h) and DR is the 555	
decay rate defined as Nascent/Total RNA73.  Half-lives were normalized to the half-life of 556	
GAPDH set at 8 h as previously determined74.  557	
 558	
Statistics and Reproducibility.  Biological replicate information is indicated in the figure 559	
legends.  All results are given as mean ± SD and analyzed by using statistical tools 560	
implemented in GraphPad Prism 7.0 software.  Statistical analyses were performed using the 561	
standard two-tailed unpaired Student’s t test with the assumption of normality for analysis or 562	
Mann-Whitney U-test of two groups.  Multiple test correction was not implemented.  563	
Differences with p < 0.05 were considered to be significant and p-value ranges are provided in 564	
each figure.  Details regarding statistical analysis are reported in each figure legend, and exact 565	
p-values for each analysis are provided as source data. 566	
 567	
Data Availability.  Source data for figures and associated statistical analysis are provided with 568	
this manuscript. The mass spectrometry proteomics data have been deposited to the 569	
ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE75 570	
partner repository with the dataset identifier PXD018773 571	
(http://www.ebi.ac.uk/pride/archive/projects/PXD018773). 572	
 573	
Code availability.  The scripts used to analyze the iPOND proteomics data are available from 574	




The authors declare no competing interests. 579	









We thank members of the Weitzman Lab for insightful discussions and input.  We are grateful 586	
to Gary H. Cohen, Roger D. Everett, David M. Knipe, Sara L. Sawyer, and Priscilla A. Schaffer 587	
for generous gifts of reagents.  C. B. was supported by the Medical Research Council 588	
(http://mrc.ukri.org) grantMC_UU_12014/5.  Work in the Weitzman lab was supported in part 589	
by grants from the National Institutes of Health (AI115104 and NS082240 to M.D.W.) and 590	
funds from the Children’s Hospital of Philadelphia.  A.M.P. was supported by the NCI T32 591	
Training Grant in Tumor Virology T32-CA115299 and Individual National Research Service 592	




E.T.K., J.M.D., E.D.R and M.D.W conceived and designed the study.  E.D.R, K.K. and B.A.G. 597	
performed iPOND mass spectrometry and subsequent analysis.  J.M.D. provided 598	
computational analysis.  E.T.K., E.D.R., A.M.P., A.O. and C.B. performed cell imaging 599	
experiments.  A.M.P. performed RNA stability assays.  E.T.K and L.N.A. performed virological, 600	
biochemical and molecular biological experiments.  E.T.K. and M.D.W. wrote the manuscript 601	
with input from all authors.602	





1. Malim, M. H. & Bieniasz, P. D. HIV Restriction Factors and Mechanisms of Evasion. 605	
Cold Spring Harb. Perspect. Med. 2, a006940 (2012). 606	
2. Gu, H. & Zheng, Y. Role of ND10 nuclear bodies in the chromatin repression of HSV-1. 607	
Virol. J. 13, 62 (2016). 608	
3. Tavalai, N. & Stamminger, T. Intrinsic cellular defense mechanisms targeting human 609	
cytomegalovirus. Virus Res. 157, 128–33 (2011). 610	
4. Glass, M. & Everett, R. D. Components of Promyelocytic Leukemia Nuclear Bodies 611	
(ND10) Act Cooperatively To Repress Herpesvirus Infection. J. Virol. 87, 2174–2185 612	
(2013). 613	
5. Crow, M. S., Lum, K. K., Sheng, X., Song, B. & Cristea, I. M. Diverse mechanisms 614	
evolved by DNA viruses to inhibit early host defenses. Crit. Rev. Biochem. Mol. Biol. 51, 615	
452–481 (2016). 616	
6. Rajsbaum, R. & García-Sastre, A. Viral evasion mechanisms of early antiviral responses 617	
involving regulation of ubiquitin pathways. Trends Microbiol. 21, 421–9 (2013). 618	
7. Dybas, J. M., Herrmann, C. & Weitzman, M. D. Ubiquitination at the interface of tumor 619	
viruses and DNA damage responses. Curr. Opin. Virol. 32, 40–47 (2018). 620	
8. Colomer-Lluch, M., Ruiz, A., Moris, A. & Prado, J. G. Restriction Factors: From Intrinsic 621	
Viral Restriction to Shaping Cellular Immunity Against HIV-1. Front. Immunol. 9, 2876 622	
(2018). 623	
9. Simon, V., Bloch, N. & Landau, N. R. Intrinsic host restrictions to HIV-1 and mechanisms 624	
of viral escape. Nat. Immunol. 16, 546–53 (2015). 625	
10. Komatsu, T., Nagata, K. & Wodrich, H. The Role of Nuclear Antiviral Factors against 626	
Invading DNA Viruses: The Immediate Fate of Incoming Viral Genomes. Viruses 8, 1–17 627	
(2016). 628	
Kim et al. 
22	
	
11. Bieniasz, P. D. Restriction factors: A defense against retroviral infection. Trends 629	
Microbiol. 11, 286–291 (2003). 630	
12. Harris, R. S., Hultquist, J. F. & Evans, D. T. The restriction factors of human 631	
immunodeficiency virus. J. Biol. Chem. 287, 40875–40883 (2012). 632	
13. Boutell, C. & Everett, R. D. Regulation of alphaherpesvirus infections by the ICP0 family 633	
of proteins. J. Gen. Virol. 94, 465–481 (2013). 634	
14. Knipe, D. M. & Cliffe, A. Chromatin control of herpes simplex virus lytic and latent 635	
infection. Nature Reviews Microbiology vol. 6 211–221 (2008). 636	
15. Cai, W. & Schaffer, P. A. Herpes simplex virus type 1 ICP0 regulates expression of 637	
immediate-early, early, and late genes in productively infected cells. J. Virol. 66, 2904–638	
2915 (1992). 639	
16. Rodríguez, M. C., Dybas, J. M., Hughes, J., Weitzman, M. D. & Boutell, C. The HSV-1 640	
ubiquitin ligase ICP0: Modifying the cellular proteome to promote infection. Virus Res. 641	
285, 198015 (2020). 642	
17. Boutell, C. & Everett, R. D. The herpes simplex virus type 1 (HSV-1) regulatory protein 643	
ICP0 interacts with and ubiquitinates p53. J. Biol. Chem. 278, 36596–36602 (2003). 644	
18. Everett, R. D., Orr, A. & Preston, C. M. A viral activator of gene expression functions via 645	
the ubiquitin-proteasome pathway. EMBO J. 17, 7161–7169 (1998). 646	
19. Lium, E. K. & Silverstein, S. Mutational analysis of the herpes simplex virus type 1 ICP0 647	
C3HC4 zinc ring finger reveals a requirement for ICP0 in the expression of the essential 648	
alpha27 gene. J. Virol. 71, 8602–8614 (1997). 649	
20. Parkinson, J., Lees-Miller, S. P. & Everett, R. D. Herpes Simplex Virus Type 1 650	
Immediate-Early Protein Vmw110 Induces the Proteasome-Dependent Degradation of 651	
the Catalytic Subunit of DNA-Dependent Protein Kinase. J. Virol. 73, 650–657 (1999). 652	
21. Lees-Miller, S. P. et al. Attenuation of DNA-dependent protein kinase activity and its 653	
catalytic subunit by the herpes simplex virus type 1 transactivator ICP0. J. Virol. 70, 654	
7471–7477 (1996). 655	
Kim et al. 
23	
	
22. Chaurushiya, M. S. et al. Viral E3 Ubiquitin Ligase-Mediated Degradation of a Cellular 656	
E3: Viral Mimicry of a Cellular Phosphorylation Mark Targets the RNF8 FHA Domain. 657	
Mol. Cell 46, 79–90 (2012). 658	
23. Lilley, C. E. et al. A viral E3 ligase targets RNF8 and RNF168 to control histone 659	
ubiquitination and DNA damage responses. EMBO J. 29, 943–55 (2010). 660	
24. Chelbi-Alix, M. K. & De Thé, H. Herpes virus induced proteasome-dependent 661	
degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18, 662	
935–941 (1999). 663	
25. Everett, R. D. et al. The Disruption of ND10 during Herpes Simplex Virus Infection 664	
Correlates with the Vmw110- and Proteasome-Dependent Loss of Several PML Isoforms. 665	
J. Virol. 72, 6581–6591 (1998). 666	
26. Perusina Lanfranca, M., Mostafa, H. H. & Davido, D. J. Two Overlapping Regions within 667	
the N-Terminal Half of the Herpes Simplex Virus 1 E3 Ubiquitin Ligase ICP0 Facilitate 668	
the Degradation and Dissociation of PML and Dissociation of Sp100 from ND10. J. Virol. 669	
87, 13287–13296 (2013). 670	
27. Lukashchuk, V. & Everett, R. D. Regulation of ICP0-Null Mutant Herpes Simplex Virus 671	
Type 1 Infection by ND10 Components ATRX and hDaxx. J. Virol. 84, 4026–4040 (2010). 672	
28. Orzalli, M. H., DeLuca, N. A. & Knipe, D. M. Nuclear IFI16 induction of IRF-3 signaling 673	
during herpesviral infection and degradation of IFI16 by the viral ICP0 protein. Proc. Natl. 674	
Acad. Sci. U. S. A. 109, E3008-17 (2012). 675	
29. Everett, R. D., Earnshaw, W. C., Findlay, J. & Lomonte, P. Specific destruction of 676	
kinetochore protein CENP-C and disruption of cell division by herpes simplex virus 677	
immediate-early protein Vmw110. EMBO J. 18, 1526–1538 (1999). 678	
30. Lomonte, P., Sullivan, K. F. & Everett, R. D. Degradation of Nucleosome-associated 679	
Centromeric Histone H3-like Protein CENP-A Induced by Herpes Simplex Virus Type 1 680	
Protein ICP0. J. Biol. Chem. 276, 5829–5835 (2001). 681	
31. Lomonte, P. & Morency, E. Centromeric protein CENP-B proteasomal degradation 682	
induced by the viral protein ICP0. FEBS Lett. 581, 658–662 (2007). 683	
Kim et al. 
24	
	
32. Perusina Lanfranca, M., Mostafa, H. H. & Davido, D. J. HSV-1 ICP0: An E3 Ubiquitin 684	
Ligase That Counteracts Host Intrinsic and Innate Immunity. Cells 3, 438–54 (2014). 685	
33. Alandijany, T. Host Intrinsic and Innate Intracellular Immunity During Herpes Simplex 686	
Virus Type 1 (HSV-1) Infection. Frontiers in Microbiology vol. 10 2611 (Frontiers Media 687	
S.A., 2019). 688	
34. Merkl, P. E., Orzalli, M. H. & Knipe, D. M. Mechanisms of Host IFI16, PML, and Daxx 689	
Protein Restriction of Herpes Simplex Virus 1 Replication. J. Virol. 92, 1–19 (2018). 690	
35. Lilley, C. E., Chaurushiya, M. S., Boutell, C., Everett, R. D. & Weitzman, M. D. The 691	
intrinsic antiviral defense to incoming HSV-1 genomes includes specific DNA repair 692	
proteins and is counteracted by the viral protein ICP0. PLoS Pathog. 7, e1002084 (2011). 693	
36. Cuchet-Lourenço, D. et al. SUMO pathway dependent recruitment of cellular repressors 694	
to herpes simplex virus type 1 genomes. PLoS Pathog. 7, e1002123 (2011). 695	
37. Sirbu, B. M. et al. Analysis of protein dynamics at active, stalled, and collapsed 696	
replication forks. Genes Dev. 25, 1320–7 (2011). 697	
38. Dembowski, J. A. & DeLuca, N. A. Selective recruitment of nuclear factors to 698	
productively replicating herpes simplex virus genomes. PLoS Pathog. 11, e1004939–699	
e1004939 (2015). 700	
39. Dembowski, J. A. & DeLuca, N. A. Temporal Viral Genome-Protein Interactions Define 701	
Distinct Stages of Productive Herpesviral Infection. MBio 9, e01182-18 (2018). 702	
40. Reyes, E. D. et al. Identifying Host Factors Associated with DNA Replicated During Virus 703	
Infection. Mol. Cell. Proteomics 16, 2079–2097 (2017). 704	
41. Liu, F., Zhou, P., Wang, Q., Zhang, M. & Li, D. The Schlafen family: complex roles in 705	
different cell types and virus replication. Cell Biol. Int. 42, 2–8 (2018). 706	
42. Mavrommatis, E., Fish, E. N. & Platanias, L. C. The schlafen family of proteins and their 707	
regulation by interferons. J. Interferon Cytokine Res. 33, 206–210 (2013). 708	
43. Katsoulidis, E. et al. Role of Interferon α (IFNα)-inducible Schlafen-5 in Regulation of 709	
Anchorage-independent Growth and Invasion of Malignant Melanoma Cells. J. Biol. 710	
Kim et al. 
25	
	
Chem. 285, 40333–41 (2010). 711	
44. Sassano, A. et al. Human Schlafen 5 (SLFN5) Is a Regulator of Motility and 712	
Invasiveness of Renal Cell Carcinoma Cells. Mol. Cell. Biol. 35, 2684–98 (2015). 713	
45. Arslan, A. D. et al. Human SLFN5 is a transcriptional co-repressor of STAT1-mediated 714	
interferon responses and promotes the malignant phenotype in glioblastoma. Oncogene 715	
36, 6006–6019 (2017). 716	
46. Li, M. et al. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 717	
11. Nature 491, 125–128 (2012). 718	
47. Seong, R. K. et al. Schlafen 14 (SLFN14) is a novel antiviral factor involved in the control 719	
of viral replication. Immunobiology 222, 979–988 (2017). 720	
48. Yang, J.-Y. et al. Structure of Schlafen13 reveals a new class of tRNA/rRNA- targeting 721	
RNase engaged in translational control. Nat. Commun. 9, 1165 (2018). 722	
49. Valdez, F. et al. Schlafen 11 restricts flavivirus replication. J. Virol. 93, 104–123 (2019). 723	
50. De La Casa-Espero’n, E. From mammals to viruses: The Schlafen genes in 724	
developmental, proliferative and immune processes. Biomol. Concepts 2, 159–169 725	
(2011). 726	
51. Kulej, K. et al. Time-resolved Global and Chromatin Proteomics during Herpes Simplex 727	
Virus Type 1 (HSV-1) Infection. Mol. Cell. Proteomics 16, S92–S107 (2017). 728	
52. Schreiner, S. et al. Proteasome-Dependent Degradation of Daxx by the Viral E1B-55K 729	
Protein in Human Adenovirus-Infected Cells. J. Virol. 84, 7029–7038 (2010). 730	
53. Dutrieux, J. et al. PML/TRIM19-Dependent Inhibition of Retroviral Reverse-Transcription 731	
by Daxx. PLoS Pathog. 11, 1–22 (2015). 732	
54. Bernassola, F. et al. Ubiquitin-dependent Degradation of p73 Is Inhibited by PML. J. Exp. 733	
Med. 199, 1545–1557 (2004). 734	
55. Louria-Hayon, I. et al. The Promyelocytic Leukemia Protein Protects p53 from Mdm2-735	
mediated Inhibition and Degradation. J. Biol. Chem. 278, 33134–33141 (2003). 736	
Kim et al. 
26	
	
56. Boutell, C. et al. A viral ubiquitin ligase has substrate preferential SUMO targeted 737	
ubiquitin ligase activity that counteracts intrinsic antiviral defence. PLoS Pathog. 7, 738	
e1002245 (2011). 739	
57. Sloan, E. et al. Analysis of the SUMO2 Proteome during HSV-1 Infection. PLoS Pathog. 740	
11, e1005059 (2015). 741	
58. Kumar, R., González-Prieto, R., Xiao, Z., Verlaan-de Vries, M. & Vertegaal, A. C. O. The 742	
STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation 743	
machinery. Nat. Commun. 8, 1809 (2017). 744	
59. Neumann, B., Zhao, L., Murphy, K. & Gonda, T. J. Subcellular localization of the 745	
Schlafen protein family. Biochem. Biophys. Res. Commun. 370, 62–66 (2008). 746	
60. Taylor, K. E., Chew, M. V, Ashkar, A. A. & Mossman, K. L. Novel roles of cytoplasmic 747	
ICP0: proteasome-independent functions of the RING finger are required to block 748	
interferon-stimulated gene production but not to promote viral replication. J. Virol. 88, 749	
8091–101 (2014). 750	
61. Lou, D. I. et al. An Intrinsically Disordered Region of the DNA Repair Protein Nbs1 Is a 751	
Species-Specific Barrier to Herpes Simplex Virus 1 in Primates. Cell Host Microbe 20, 752	
178–188 (2016). 753	
62. Alandijany, T. et al. Distinct temporal roles for the promyelocytic leukaemia (PML) 754	
protein in the sequential regulation of intracellular host immunity to HSV-1 infection. 755	
PLoS Pathog. 14, e1006769–e1006769 (2018). 756	
63. Geserick, P., Kaiser, F., Klemm, U., Kaufmann, S. H. E. & Zerrahn, J. Modulation of T 757	
cell development and activation by novel members of the Schlafen (slfn) gene family 758	
harbouring an RNA helicase-like motif. Int. Immunol. 16, 1535–1548 (2004). 759	
64. Stabell, A. C. et al. Non-human primate schlafen11 inhibits production of both host and 760	
viral proteins. PLOS Pathog. 12, e1006066 (2016). 761	
65. Stow, N. D. & Stow, E. C. Isolation and Characterization of a Herpes Simplex Virus Type 762	
1 Mutant Containing a Deletion within the Gene Encoding the Immediate Early 763	
Polypeptide Vmw110. J. Gen. Virol. 67, 2571–2585 (1986). 764	
Kim et al. 
27	
	
66. Everett, R. D. Construction and Characterization of Herpes Simplex Virus Type 1 765	
Mutants with Defined Lesions in Immediate Early Gene 1. J. Gen. Virol. 70, 1185–1202 766	
(1989). 767	
67. Sirbu, B. M., Couch, F. B. & Cortez, D. Monitoring the spatiotemporal dynamics of 768	
proteins at replication forks and in assembled chromatin using isolation of proteins on 769	
nascent DNA. Nat. Protoc. 7, 594–605 (2012). 770	
68. Stacklies, W., Redestig, H., Scholz, M., Walther, D. & Selbig, J. pcaMethods - A 771	
bioconductor package providing PCA methods for incomplete data. Bioinformatics 23, 772	
1164–1167 (2007). 773	
69. Pascovici, D., Handler, D. C. L., Wu, J. X. & Haynes, P. A. Multiple testing corrections in 774	
quantitative proteomics: A useful but blunt tool. Proteomics 16, 2448–2453 (2016). 775	
70. Halford, W. P., Kemp, C. D., Isler, J. A., Davido, D. J. & Schaffer, P. A. ICP0, ICP4, or 776	
VP16 Expressed from Adenovirus Vectors Induces Reactivation of Latent Herpes 777	
Simplex Virus Type 1 in Primary Cultures of Latently Infected Trigeminal Ganglion Cells. 778	
J. Virol. 75, 6143–6153 (2001). 779	
71. Poling, B. C., Price, A. M., Luftig, M. A. & Cullen, B. R. The Epstein-Barr virus miR-780	
BHRF1 microRNAs regulate viral gene expression in cis. Virology 512, 113–123 (2017). 781	
72. Russo, J., Heck, A. M., Wilusz, J. & Wilusz, C. J. Metabolic labeling and recovery of 782	
nascent RNA to accurately quantify mRNA stability. Methods 120, 39–48 (2017). 783	
73. Price, A. M., Messinger, J. E. & Luftig, M. A. c-Myc Represses Transcription of Epstein-784	
Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection. J. Virol. 92, 785	
e01178-17 (2018). 786	
74. Dölken, L. et al. High-resolution gene expression profiling for simultaneous kinetic 787	
parameter analysis of RNA synthesis and decay. RNA 14, 1959–1972 (2008). 788	
75. Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: 789	
Improving support for quantification data. Nucleic Acids Res. 47, D442–D450 (2019). 790	
791	





Fig. 1 | ICP0 targets SLFN5 for degradation.  a, Workflow schematic showing how iPOND-MS was combined 793	
with PCA-based clustering to identify cellular substrates of ICP0.  b, Plot highlights a trend in differential 794	
abundance for known ICP0 substrates across iPOND proteomes at 8 hpi.  c, PCA-based clustering of proteins 795	
identified in iPOND-MS proteomes by abundance similarity to known ICP0 substrates.  Proteins are projected 796	
onto a 3D PCA space.  Indicated known restriction factors are assigned as cluster centers.  Proteins were 797	
clustered based on their proximity to cluster centers in 3D PCA space.  d, HFF cells were infected with HSV-1 WT 798	
or ΔICP0 mutant virus at an MOI of 3 and iPOND isolation of SLFN5 was examined at 8 hpi.  e, Comparison of 799	
changes in protein abundance of ICP0 targets during HSV-1 infection.  Whole cell proteome analysis reveals 800	
SLFN5 protein reduction during HSV-1 infection.  f, Comparison with known ICP0 substrate proteins reveals 801	
SLFN5 degradation is dependent on the ICP0 RING finger domain and that SLFN11 is not degraded.  g, SLFN5 802	
turnover is proteasome-dependent.  The proteasome inhibitor MG132 was added at 2 hpi and lysates were 803	
prepared for immunoblotting at indicated time points.  h, The turnover rate of SLFN5 in WT or ΔRING mutant-804	
infected HFF cells was compared by cycloheximide (CHX) chase followed by densitometric analysis of 805	
immunoblots.  Data are the mean ± SD.  Comparisons between groups were performed using the two-tailed 806	
unpaired Student's t-test.  **, p < 0.005.  n = 3 biologically independent experiments. Immunoblots show 807	
representative data from n = 3 biologically independent experiments. 808	
 809	
 810	
Fig. 2 | ICP0 interacts with SLFN5.  a, Ubiquitination of endogenous SLFN5 by ICP0 expressed by inducible 811	
recombinant adenoviruses vector transduction.  Denaturing immunoprecipitation (IP) was carried out with anti-Ub 812	
antibody and SLFN5 detected by immunoblot (IB).  b, SLFN5 degradation is PML-independent and is detected in 813	
cells with PML depleted.  c, HFF cells infected with HSV-1 WT or ΔRING virus at MOI of 3 were subject 814	
to immunofluorescence with antibodies to ICP0 and SLFN5.  Scale bar, 10 µm.  The fluorescence plot profiles (at 815	
dashed lines) were analyzed by ImageJ.  d, Quantification of the colocalization coefficient showed colocalization 816	
of ICP0 with SLFN5 at early infection times of both viruses.  Each box plot represents five cells per condition with 817	
whiskers from minimum to maximum, median indicated by horizontal bar in the box, and box limits extending from 818	
quartile 1 to quartile 3.  Data are the mean ± SD.  Comparisons between groups were performed using the two-819	
tailed unpaired Student's t-test.  ***, p < 0.0005.  n.s., not significant.  e, ICP0 was immunoprecipitated from HSV-820	
1 infected HFF cells and immunoblot detected interaction with endogenous SLFN5 at 2 hpi.  f, ICP0 interacts 821	
through the C-terminal region of SLFN5.  HEK293T cells were co-transfected with plasmids encoding ICP0 822	
ΔRING and full-length or mutants of GFP-SLFN5.  Proteins were immunoprecipitated with anti-GFP Ab, followed 823	
by immunoblotting.  g, Schematic structure of full-length and mutant SLFN5 proteins.  The relative strength [%] of 824	
each interaction compared to full-length was determined by densitometric analysis of co-purified ICP0 protein 825	
bands.  h, ICP0 interacts with SLFN5, but not with SLFN11.  Co-IP were carried out with plasmids co-transfected 826	
cells in the presence of benzonase.  i, In vitro ubiquitination assays with bacterially purified or in vitro translated 827	
proteins reveal that ICP0 ubiquitinates SLFN5 directly, but not SLFN11. Immunoblots show representative data 828	
from n = 3 biologically independent experiments. 829	
 830	
Fig. 3 | SLFN5 colocalizes with HSV-1 DNA.  HFF cells were infected at an MOI of 1 with HSV-1EdC and 831	
samples fix at the indicated times post-infection.  Input viral DNA (vDNA) was detected by click chemistry (red). 832	
SLFN5 (green) and PML (cyan) were detected by indirect immunofluorescence.  Nuclei were stained with DAPI 833	
(blue).  a, Representative confocal microscopy images showing colocalization of SLFN5 and vDNA.  Green and 834	
cyan arrows highlight examples of SLFN5 and PML colocalization at vDNA, respectively.  Inserts; magnified 835	
regions of interest (boxes). Cut mask images (yellow) show regions of SLFN5 or PML (as indicated) colocalization 836	
at vDNA. W. colocalization coefficients shown (0 = no colocalization; 1 = perfect colocalization).  Scale bar, 10 µm  837	
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b, Scatter plots showing paired weighted (w.) colocalization coefficients of SLFN5 and PML at vDNA per nuclei.  838	
Grey and red lines indicate arbitrary weighted colocalization coefficient gating at 0.2 and 0.7, respectively.  c, 839	
Violin plots showing weighted colocalization coefficients of SLFN5 or PML at vDNA.  Black line; median:  Dotted 840	
lines; 5 and 95th percentile range:  Grey line; threshold of detection (0.2). ** p < 0.01, **** p < 0.0001;  Dunn’s 841	
multiple comparison test (n90mpi = 126, n180mpi = 155, n240mpi = 193 over 3 biological replicates).  d, 842	
Immunofluorescence for SLFN5 and viral DNA (vDNA).  HFF cells were infected with WT HSV-1 or ΔICP0 mutant 843	
virus at an MOI of 3 prior to overlay with medium containing 0.5 µM EdC and 50 µM ACG.  Samples were fixed at 844	
6 hpi.  De novo nascent vDNA synthesis was detected by click chemistry (red) and SLFN5 (green) by indirect 845	
immunofluorescence.  Representative confocal microscopy images showing nuclear localization of SLFN5 at 846	
vDNA.  White arrows highlight examples of SLFN5 localization at vDNA.  Cut mask images (yellow) show region 847	
of SLFN5 colocalization at vDNA.  Colocalization coefficients shown (0 = no colocalization; 1 = perfect 848	
colocalization).  Scale bar, 10 µm  e, Violin plots showing weighted colocalization coefficients of SLFN5 at vDNA.  849	
Black line; median; Dotted lines; 5 and 95th percentile range; Grey line; threshold of detection (0.2). n ≥ 100 850	
infected cells per sample population derived from 3 independent experiments. **** p < 0.0001; Mann-Whitney U-851	
test (nHSV-1 = 122, nΔICP0 = 114 over three biological replicates).  f, 3D reconstruction of high-resolution Z-series 852	
confocal image showing SLFN5 (green) entrapment of HSV-1 DNA EdC vDNA (red).  Scale bar, 0.4 µm. 853	
 854	
Fig. 4 | ICP0 counteracts SLFN5-mediated suppression of HSV-1 replication.  HeLa cells stably depleted for 855	
SLFN5 by shRNA were infected with HSV-1 at an MOI of 0.1.  HSV-1 replication was monitored by qPCR (a) and 856	
plaque assays (b).  n = 3 biologically independent experiments.  c, HSV-1 replication in siRNA-transfected HFF 857	
cells was monitored by viral DNA qPCR.  n = 3 biologically independent experiments.  d, HeLa cells were stably 858	
transduced with control lentivirus (Tet.Vector-HA) or lentivirus containing tetracycline-inducible SLFN5-HA gene 859	
(Tet.SLFN5-HA).  SLFN5-HA was induced with doxycycline (0.5 µg/ml) for 48 h.  Cells were infected with HSV-1 860	
WT or ΔRING virus at an MOI of 0.1.  At 24 hpi, viral DNA was measured by qPCR.  n = 4 biologically 861	
independent experiments.  SLFN5 expression was confirmed by immunoblotting.  e, f, Walker A motif mutant 862	
(K584A) showed similar restriction as WT SLFN5.  Recombinant adenoviral transduction system was used for 863	
ectopic expression of SLFN5 proteins.  Transduced cells for 24 h were infected with ΔRING at an MOI of 3 (e) or 864	
an MOI of 0.1 (f) and HSV-1 infectivity was analyzed by immunoblotting (e) and plaque assays (f).  n = 3 865	
biologically independent experiments.  g, h, Transient knockdown of SLFN5 or SLFN11. The cells were infected 866	
ΔRING at an MOI of 3 (g) or an MOI of 0.1 (h).  Viral protein at 9 hpi was analyzed by immunoblotting (g) and 867	
viral DNA at 24 hpi was monitored by qPCR (h).  n = 6 biologically independent experiments.  Data are the mean 868	
±SD.  Comparisons between groups were performed using the two-tailed unpaired Student's t-test.  *, p < 0.05, **, 869	
p < 0.005, ***, p < 0.0005.  n.s., not significant. Immunoblots show representative data from n = 3 biologically 870	
independent experiments. 871	
 872	
Fig. 5 | SLFN5 associates with vDNA to suppress HSV-1 gene transcription.  a, Control and SLFN5-depleted 873	
HeLa cells were infected with ΔRING virus at an MOI of 3 in the absence or presence of phosphonoacetic acid 874	
(PAA, 200 µg/ml).  Accumulation of viral DNA and mRNA (ICP27 and TK) was measured by qPCR and RT-qPCR, 875	
respectively.  n = 3 biologically independent experiments.  b, Accumulation of viral proteins were analyzed by 876	
immunoblot analysis (representative data from n = 3 biologically independent experiments).  c, 4sU metabolic 877	
pulsing reveals SLFN5-mediated suppression of viral gene transcription.  Schematic of 4sU experiments (top).  878	
Cells were pulsed for 30 min at 5.5 hpi with ΔRING virus at an MOI of 3.  Total RNA was isolated and 4sU-labeled 879	
RNA was then conjugated to biotin and isolated by use of streptavidin beads.  Total mRNA or nascent mRNA of 880	
ICP27 and TK were analyzed by RT-qPCR.  n = 3 biologically independent experiments.  d, RT-qPCR analysis of 881	
mRNA half-lives from 4sU experiments.  Half-lives were normalized to that for GAPDH.  n  = 3 biologically 882	
independent experiments.  e, ChIP assays with anti-RNAP II specific antibody was performed in control or 883	
SLFN5-silenced HeLa cells infected with ΔRING at 3 hpi.  n = 3 biologically independent experiments.  f, ChIP 884	
assays with anti-RNAP II specific antibody was performed in control or SLFN5-silenced HeLa cells infected with 885	
ΔRING at an MOI of 1 or 10 for 3 h.  n = 3 biologically independent experiments.  g, ΔRING virus replication was 886	
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monitored by plaque assays at 15 hpi.  n = 3 biologically independent experiments.  Data are the mean ± SD.  887	
Comparisons between groups were performed using the two-tailed unpaired Student's t-test.  *, p < 0.05, **, p < 888	
0.005, n.s., not significant.  h, Model for SLFN5 association with the viral genome and inhibition of transcription by 889	
minimizing RNAP II accessibility in the absence of ICP0.  ICP0 degrades SLFN5 to promote transcription of viral 890	
genes.  891	
